An ADAM17/TACE inhibitory antibody INCB7839 (Aderbasib), in combination with rituximab, is in phase I/II clinical trial as consolidation therapy after autologous hematopoietic cell transplant for patients with diffuse large B cell lymphoma (clinicaltrials.gov identifier: NCT02141451). The gene discussed is ADAM17; the disease is diffuse large B-cell lymphoma.